Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Brigatinib (Alunbrig) has been added to the NCCN Guidelines for Central Nervous System Cancers for NF2-related schwannomatosis, a rare genetic condition affecting roughly 1 in 30,000 people. The phase 2 INTUITT-NF2 trial showed tumor responses across multiple tumor types, with the best results in meningiomas and nonvestibular schwannomas. The guideline inclusion now gives clinicians a pathway to seek insurance approval for this off-label therapy.
NF2-related schwannomatosis is a rare genetic disorder that causes multiple tumors to grow along nerves — and until now, patients had very limited medical treatment options. The phase 2 INTUITT-NF2 trial tested brigatinib (Alunbrig), an oral agent, in 40 patients with progressive disease and found meaningful tumor responses, particularly in meningiomas and nonvestibular schwannomas. The drug was well tolerated, with no grade 4 or 5 treatment-related adverse events reported, and some patients remained on therapy for over two years with continued benefit.
Because the trial was too small to support FDA approval, brigatinib remains an off-label option — but its recent addition to the NCCN Guidelines for Central Nervous System Cancers is a significant development. The guideline listing gives clinicians a recognized, expert-backed basis to request insurance coverage for patients who need it, and opens the door to earlier use of the drug to slow tumor growth and potentially reduce the need for repeated surgeries.
By the Numbers
Why it matters: For patients with a condition so rare that pharmaceutical investment is scarce, NCCN guideline inclusion is a critical step — it doesn't just validate the science, it unlocks real-world access to a therapy that could meaningfully improve quality of life.
